Topiramate is a novel antiepileptic drug (AED) which exerts its action through (1) blocking of voltage gated sodium channel, (2) increase of GABAergic activity through stimulation of the non benzodiazepine site of the GABAA receptors, (3) antagonising the glutamate kainate/AMPA receptor. After an observation period of 4 weeks during which subjects reported the frequency and severity of migraine attacks, we have conducted in a 3 months study evaluating the effectiveness and safety of topiramate used as prophylaxis of migraine attacks in 20 patients selected according to the IHS criteria. No patient interrupted the study and topiramate resulted well tolerated; adverse events (dizziness, ataxia, paresthesia, disartria) were mostly transitory and of mild to moderate severity. The preliminary results of this study reveal a significant reduction in the frequency of attacks in the study sample. Although the number of study participants was too low to enable definite conclusions, the results suggest that topiramate represents an interesting candidate for future placebo controlled studies, and that this drug could feature a valid alternative to traditional anti-migraine prophylactic agents.
|Translated title of the contribution||Topiramate as prophylactic treatment in migraine|
|Number of pages||5|
|Journal||Acta Medica Romana|
|Publication status||Published - 2000|
ASJC Scopus subject areas